Venetoclax (ABT-199) was developed to specifically inhibit BCL2 with only weak activity towards other members of the BCL2 family, including BCLxL thereby minimising thrombocytopaenia as a dose-limiting toxicity[84]. This evidence concerns the gene BCL2 and Thrombocytopenia.